17th May 2022 – VAC85135 is a novel clinical candidate developed by Nouscom and Janssen under a multi-project agreement Nouscom, a clinical stage immuno-oncology company developing both [...]
Nouscom recently published in the Journal for ImmunoTherapy of Cancer a manuscript entitled: “Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, [...]
10th November 2021 – Results presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and [...]
6th September 2021 – Our abstract “Initial Results from a Phase I Study of NOUS-209, an Off-the-Shelf Viral Vectored Immunotherapy Encoding 209 Shared Frame Shift Peptide Neoantigens, with [...]
BASEL, Switzerland – August 24th, 2021: Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, today announced that the first [...]
Dr. Marina Udier looks forward to presenting @Chardan for their 5th Annual Genetic Medicines Conference on October 4th at 3 pm CET. Nouscom is one of 90+ public and private genetic medicines [...]
VENUS (Vaccine-Encoded Neoantigens Unrestricted Selection) is Nouscom’s proprietary algorithm designed to enhance the predictive accuracy of personalized neoantigen selections that may induce an [...]
Our head of Preclinical and Clinical Immunology Anna Morena D’alise will join as Expert Speaker at the Next Generation Cancer Vaccine Development Summit from September 7 – 9, 2021. You can [...]
BASEL, Switzerland – 11th March 2021: Nouscom, a clinical stage immuno-oncology biotech developing next generation viral-vector based immunotherapies, today announces it has received approval [...]
The Next aCGT Europe Needs to Leapfrog — How? Follow the link below for more details. https://lnkd.in/dpAnmJZ
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.
